Machine learning is an essential component of artificial intelligence. Whether it’s powering recommendation engines, fraud detection systems, self-driving cars, generative AI, or any of the countless ...

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

Currently, the Python extension only supports “Run Selection/Line in Native Python REPL”. However, there is no built-in command to run the entire file in the Native Python REPL environment, similar to ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Kara Alaimo is a professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was published ...

Anthropic is starting to train its models on new Claude chats. If you’re using the bot and don’t want your chats used as training data, here’s how to opt out. Anthropic is prepared to repurpose ...

Main Street’s not dazzled by AI’s big promises. Small businesses are testing it cautiously, leaning on features tucked into their daily software. A little over a year ago, the U.S. Chamber of Commerce ...

Officials estimate that pythons have killed 95% of small mammals as well as thousands of birds in Everglades National Park South Florida Water Management District via AP; AP Photo/Lynne Sladky ...

Kara Alaimo is an associate professor of communication at Fairleigh Dickinson University. Her book “Over the Influence: Why Social Media Is Toxic for Women and Girls — And How We Can Take It Back” was ...

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...